FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 342:810-811 March 16, 2000 Number 11 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Lovell, D. J. PubMed Citation

For patients with rheumatoid arthritis, a new era in treatment has begun. This optimistic view, shared widely by rheumatologists, reflects the introduction in the past two years of novel agents to treat this painful and debilitating condition. These agents, including the tumor necrosis factor (TNF) blockers, are the fruits of biotechnology and bring improvements in efficacy and safety. Furthermore, children will be among the candidates for these new treatments, since as shown by the results reported by Lovell et al. in this issue of the Journal,¹ children with juvenile rheumatoid arthritis, like adults, have an impressive response to TNF blockade.

. . . [Full Text of this Article]

References

This article has been cited by other articles:

• Farasat, S., Aksentijevich, I., Toro, J. R. (2008). Autoinflammatory Diseases: Clinical and Genetic Advances. Arch Dermatol 144: 392-402 [Abstract] [Full Text]  
• Yoh, K., Shibuya, K., Morito, N., Nakano, T., Ishizaki, K., Shimohata, H., Nose, M., Izui, S., Shibuya, A., Koyama, A., Engel, J. D., Yamamoto, M., Takahashi, S. (2003). Transgenic Overexpression of GATA-3 in T Lymphocytes Improves Autoimmune Glomerulonephritis in Mice with a BXSB/MpJ-Yaa Genetic Background. J. Am. Soc. Nephrol. 14: 2494-2502 [Abstract] [Full Text]  
• Wulffraat, N M, Haas, P J, Frosch, M, de Kleer, I M, Vogl, T, Brinkman, D M C, Quartier, P, Roth, J, Kuis, W (2003). Myeloid related protein 8 and 14 secretion reflects phagocyte activation and correlates with disease activity in juvenile idiopathic arthritis treated with autologous stem cell transplantation. Ann Rheum Dis 62: 236-241 [Abstract] [Full Text]  
• Agusti, A.G.N., Noguera, A., Sauleda, J., Sala, E., Pons, J., Busquets, X. (2003). Systemic effects of chronic obstructive pulmonary disease. Eur Respir J 21: 347-360 [Abstract] [Full Text]  
• Ferrajoli, A., Keating, M. J., Manshouri, T., Giles, F. J., Dey, A., Estrov, Z., Koller, C. A., Kurzrock, R., Thomas, D. A., Faderl, S., Lerner, S., O'Brien, S., Albitar, M. (2002). The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia. Blood 100: 1215-1219 [Abstract] [Full Text]  
• Garcia-Porrua, C., Gonzalez-Gay, M. A. (2002). Successful treatment of refractory mononeuritis multiplex secondary to rheumatoid arthritis with the anti-tumour necrosis factor {alpha} monoclonal antibody infliximab. Rheumatology (Oxford) 41: 234-235 [Full Text]  
• Bleumink, G. S., ter Borg, E. J., Ramselaar, C. G., Ch. Stricker, B. H. (2001). Etanercept-induced subacute cutaneous lupus erythematosus. Rheumatology (Oxford) 40: 1317-1319 [Full Text]  
• Davidson, A., Diamond, B. (2001). Autoimmune Diseases. NEJM 345: 340-350 [Full Text]  
• Quattrocchi, E., Dallman, M. J., Dhillon, A. P., Quaglia, A., Bagnato, G., Feldmann, M. (2001). Murine IL-10 Gene Transfer Inhibits Established Collagen-Induced Arthritis and Reduces Adenovirus-Mediated Inflammatory Responses in Mouse Liver. J. Immunol. 166: 5970-5978 [Abstract] [Full Text]  
• Toro, J. R., Aksentijevich, I., Hull, K., Dean, J., Kastner, D. L. (2000). Tumor Necrosis Factor Receptor-Associated Periodic Syndrome: A Novel Syndrome With Cutaneous Manifestations. Arch Dermatol 136: 1487-1494 [Abstract] [Full Text]